Is Moderna, Inc. (MRNA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 6.3% / 30% | 28.0% / 30% | 1.4% / 30% | 16.34% / 5% | ✗ NOT HALAL |
| DJIM | 6.3% / 33% | 28.0% / 33% | 1.4% / 33% | 16.34% / 5% | ✗ NOT HALAL |
| MSCI | 10.6% / 33% | 47.0% / 33% | 2.3% / 33% | 16.34% / 5% | ✗ NOT HALAL |
| S&P | 6.3% / 33% | 28.0% / 33% | 1.4% / 33% | 16.34% / 5% | ✗ NOT HALAL |
| FTSE | 10.6% / 33% | 47.0% / 33% | 2.3% / 50% | 16.34% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -105.8% | |
| Operating Margin | -126.4% | |
| Net Margin | -145.2% | |
| Return on Equity (ROE) | -28.9% | |
| Return on Assets (ROA) | -14.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$1.9B |
| Free Cash Flow | -$2.1B |
| Total Debt | $1.3B |
| Debt-to-Equity | 15.1 |
| Current Ratio | 3.3 |
| Total Assets | $12.3B |
Price & Trading
| Last Close | $53.57 |
| 50-Day MA | $48.60 |
| 200-Day MA | $33.09 |
| Avg Volume | 11.4M |
| Beta | 1.4 |
|
52-Week Range
$22.28
| |
About Moderna, Inc. (MRNA)
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Moderna, Inc. (MRNA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Moderna, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Moderna, Inc.'s debt ratio?
Moderna, Inc.'s debt ratio is 6.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.6%.
What are Moderna, Inc.'s key financial metrics?
Moderna, Inc. has a market capitalization of $19.7B, and revenue of $1.9B. The company maintains a gross margin of -105.8% and a net margin of -145.2%. Return on equity stands at -28.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.